Cellino is developing a scalable, automated biomanufacturing system that produces personalized cell therapies using patient-derived cells. This technology addresses the challenges of high costs and lengthy production times in delivering potentially curative treatments for individual patients.
Funding
$99.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ARFounders
Product
Problem
Manufacturing patient-specific cell therapies is currently expensive, time-consuming, and difficult to scale, hindering widespread access to these potentially curative treatments. Traditional manual cell culture methods introduce variability and limit the ability to precisely control the biomanufacturing process.
Solution
Cellino is developing the Nebula™ platform, an AI-driven, automated biomanufacturing system for personalized cell therapies. The platform utilizes laser-based cell management and image-guided optical bioprocesses to precisely control cell density and remove unwanted cells, ensuring consistent and reproducible results. By compressing traditional infrastructure into modular, cassette-based systems, Nebula™ enables scalable deployment in both centralized foundries and localized hospital settings. This approach aims to reduce manufacturing costs, accelerate production timelines, and expand patient access to advanced regenerative medicine.
Target Audience
The primary target audience includes cell therapy developers, hospitals, and research institutions seeking to streamline and scale the manufacturing of personalized cell therapies for various degenerative diseases.
Features
- AI-powered algorithms for reproducible and scalable biomanufacturing
- Laser-generated bubbles for precise removal of unwanted cells and density control
- Image-guided optical bioprocess for consistent results and minimized human variability
- Modular, cassette-based Nebula™ systems for scalable deployment
- Closed-loop system minimizing the need for human intervention
- Digital environment simulating biomanufacturing behavior in silico (Cellinoverse)
- Capability to manufacture autologous iPSC therapies, eliminating the need for immunosuppression